Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy. [PDF]
Int J Rheum DisABSTRACT Introduction This study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)‐associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.
Ohkubo N +7 more
europepmc +3 more sources
Thrombotic Thrombocytopenic Purpura [PDF]
Journal of Associated Medical Sciences, 2015 -
Nuchanat Nonsee, Prasit Chanarat
doaj +6 more sources
Hereditary thrombotic thrombocytopenic purpura
Haematologica, 2019 The first description of thrombotic thrombocytopenic purpura (TTP) by Moschowitz was published nearly 100 years ago.[1][1] This was likely to have been an immune-mediated TTP episode and the author described multi organs affected with worsening, untreated disease.
Marie Scully
doaj +9 more sources
Thrombotic thrombocytopenic purpura [PDF]
Nature Reviews Disease Primers, 2017 Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic anaemia and a variable degree of ischaemic organ damage, particularly affecting the brain, heart and kidneys.
Kremer Hovinga, Johanna A. +5 more
semanticscholar +8 more sources
How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. [PDF]
Br J HaematolThe use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Weisinger J +4 more
europepmc +2 more sources
Vaccination and Thrombotic Thrombocytopenic Purpura
Turkish Journal of Hematology, 2020 In the adult age group, vaccines did not contribute to the development of immune thrombocytopenia (ITP), but an increase was reported in diphtheria-tetanus-pertussis-poliomyelitis vaccines without statistical significance [2].
I. Yavaşoğlu
openaire +5 more sources
Effect of blood groups on acquired and congenital thrombotic thrombocytopenic purpura and clinical correlation: Multi-center Turkish cohort study [PDF]
Hematology, Transfusion and Cell TherapyBackground: Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic hemolytic anemia associated with ADAMTS-13 deficiency, a cleaving protease of von Willebrand factor (vWF).
Cevat İlteriş Kıkılı +4 more
doaj +2 more sources
A Case of Acute Kidney Injury During Eltrombopag Use Successfully Treated With Plasma Exchange in Addition to Antithrombotic Therapy [PDF]
Kidney MedicineEltrombopag (EPAG), a thrombopoietin receptor agonist, has emerged as a valuable option for the treatment of immune thrombocytopenic purpura. However, its use has raised concerns regarding thrombotic complications.
Noriko Ueno +10 more
doaj +2 more sources
Inherited thrombotic thrombocytopenic purpura
Haematologica, 2009 Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia accompanied by variable neurological dysfunction, renal failure and fever.[1][1] Lesions consist of vessel wall thickening (mainly arterioles ...
Miriam Galbusera +2 more
doaj +4 more sources
Novel Mutation of Upshaw-Schulman Syndrome Associated with Coarctation of Aorta in Palestinian Child [PDF]
Ķazaķstannyṇ Klinikalyķ Medicinasy, 2020 Upshaw-Schulman syndrome is a rare inherited form of thrombotic thrombocytopenic purpura disease caused by deficiency of ADAMTS13 and reversible by fresh frozen plasma infusions.
Mahdi Zaid +5 more
doaj +1 more source